Ultragenyx Pharmaceutical (RARE) Revenue Growth (1y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 64.24% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.82% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 19.04% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3,790.58% |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn | -2.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.16% |
| Dec 31, 2025 | 25.89% |
| Sep 30, 2025 | 14.65% |
| Jun 30, 2025 | 13.24% |
| Mar 31, 2025 | 27.72% |
| Dec 31, 2024 | 29.50% |
| Sep 30, 2024 | 42.27% |
| Jun 30, 2024 | 35.75% |
| Mar 31, 2024 | 8.30% |
| Dec 31, 2023 | 23.02% |
| Sep 30, 2023 | 8.10% |
| Jun 30, 2023 | 21.23% |
| Mar 31, 2023 | 25.72% |
| Dec 31, 2022 | 23.93% |
| Sep 30, 2022 | 11.09% |
| Jun 30, 2022 | 2.72% |
| Mar 31, 2022 | -19.58% |
| Dec 31, 2021 | -8.91% |
| Sep 30, 2021 | 0.22% |
| Jun 30, 2021 | 40.94% |
| Mar 31, 2021 | 173.75% |
| Dec 31, 2020 | 157.19% |
| Sep 30, 2020 | 215.78% |
| Jun 30, 2020 | 155.53% |
| Mar 31, 2020 | 99.81% |
| Dec 31, 2019 | 118.89% |
| Sep 30, 2019 | 119.33% |
| Jun 30, 2019 | 88.75% |
| Mar 31, 2019 | 70.20% |
| Dec 31, 2018 | 674.33% |
| Sep 30, 2018 | 5,840.91% |
| Dec 31, 2017 | 41,900.00% |
| Sep 30, 2017 | 78.38% |